Insight

Akhil Santhosh

Apr 9, 2025, 02:49

Akhil Santhosh: Toripalimab plus axitinib in patients with stage 4 mucosal melanoma

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:

“Toripalimab plus axitinib in patients with stage 4 mucosal melanoma: 3-year survival update and biomarker analysis

9pts phase data
Median PFS 7.5m
3 year OS 3%
gene GEP correlates with increased PFS and OS.”

“Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis”

Authors: Siming Li, Xiaowen Wu, Xieqiao Yan, Li Zhou, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Jie Dai, Yan Kong, Xiongwen Tang, Hui Feng, Sheng Yao, Keith T Flaherty, Jun Guo, Xinan Sheng

Akhil Santhosh

Akhil Santhosh Bin Lian Bixia Tang cancer Chuanliang Cui Hui Feng Jie Dai Jun Guo Keith T. Flaherty Li Zhou Lili Mao Lu Si OncoDaily Oncology Sheng Yao Siming Li Xiaowen Wu Xieqiao Yan Xinan Sheng Xiongwen Tang Xuan Wang Xue Bai Yan Kong Zhihong Chi

HYPO-RT-PC Phase III trial: Two-Week Radiotherapy Proven as Safe and Effective as Eight-Week Course for Prostate Cancer, After 10-Year Follow-Up

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer

NIVOPOSTOP (GORTEC 2018-01): A Phase III Trial of Adjuvant Nivolumab in High-Risk Resected Head and Neck Squamous Cell Carcinoma

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Bianca Balti: The Supermodel’s Brave Battle with Ovarian Cancer